Levels of Inflammation in Middle East People With Cardiovascular Disease With/Without Kidney Disease

A Cross-sectional Study to Investigate Prevalence of Systemic Inflammation (hsCRP) in Cohort of Patients With HF and a Cohort of Patients With ASCVD and CKD in the Middle East

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06655493

Acronym

INFLAMEAST

Enrollment

756

Registered

2024-10-23

Start date

2024-11-22

Completion date

2025-08-28

Last updated

2025-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic Inflammation (hsCRP)

Brief summary

This study will collect medical and background information from participants with diseases that affect the heart and blood vessels (cardiovascular disease) with/without kidney disease. The aim of the study is to assess the number of people with high levels of systemic inflammation among Middle East people with cardiovascular with/without kidney disease. Systemic inflammation means that it occurs throughout the body. Participation in this study only requires a single visit at the clinic/hospital/medical institution. Participants will continue their normal care and will not get any treatment as part of this study.

Interventions

OTHERNo treatment given

Participants will continue their normal care and will not get any treatment as part of this study.

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol). 2. Male or female, age above or equal to 18 years at the time of signing informed consent. 3. Diagnosed with ASCVD+CKD and/or HF (pEF or mrEF)

Exclusion criteria

1. Previous participation in this study. Participation is defined as having given informed consent in this study. 2. Current participation (i.e., signed informed consent) in any other interventional clinical study. 3. Any hospitalization or unplanned visit within the last 60 days (including exacerbation of chronic disease with hospitalization). 4. Clinical evidence, or suspicion of, active infection within the last 60 days. 5. Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.

Design outcomes

Primary

Measure	Time frame	Description
High Sensitivity C-Reactive Protein (hsCRP) ≥2 mg/L	At Visit (day 0)	Count of patients

Countries

Saudi Arabia, United Arab Emirates

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026